M.D. Anderson Cancer Center
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and the recommended Phase 2 dose of ivonescimab that can be given to patients who have recurrent glioblastoma. The goal of Phase 2 of this clinical research study is to learn if the recommended Phase 2 dose of ivonescimab found in Phase 1 can help to control the disease.
Primary Objectives: * To determine the safety and tolerability of ivonescimab in adult patients with recurrent glioblastoma * To determine the median progression free survival and progression free survival rate at 6 months of ivonescimab in adult patients with recurrent glioblastoma
Inclusion Criteria: 1. Age ≥18 years 2. Karnofsky Performance Status (KPS) of 60 or greater 3. Recurrent supratentorial Glioblastoma that has progressed following standard therapy; patients must have previously been treated with radiation with or without temozolomide. 1. Patients will be eligible at first or second recurrence. 2. Patients must be greater than 12 weeks from completion of initial chemoradiation at the time of progression, with the exception that patients with biopsy-confirmed recurrent disease prior to this time window can be enrolled. 4. Diagnosis of Glioblastoma IDH-wi…
Participante will recived an infusion by vein
Arctuva estimate
Verify or correct the compensation shown for this listing.